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Efficacy of a Patient-Activated Pharmacologic Pump Using Phenylephrine
as Active Drug and Prodromal Symptoms as a Marker of
Imminent Loss of Consciousness to Abort Tilt-Induced Syncope
To the Editor: An implantable drug-delivery system (DDS) re-
cently has been proposed as a potentially useful treatment for
severely symptomatic patients with vasovagal syncope (VVS) (1,2).
In the present study, we assessed, during head-up tilt tests
(HUTTs), the usefulness of a prototype of a patient-activated
DDS that uses phenylephrine as an active agent and prodromal
symptoms as a marker of imminent loss of consciousness.
In this single patient-blind, randomized study, each patient
underwent two consecutive HUTTs. In one test, a bolus of
phenylephrine (1 mg/1 ml) was injected into the right atrium
during the time when a VVS developed and blood pressure
decreased by more than 50%; in the other, the same volume of
placebo (saline solution) was delivered. The study consisted of two
phases. During the first phase (physician test), phenylephrine and
placebo were injected by the attending physician by means of a
syringe. In the second phase (patient test), phenylephrine and
placebo were delivered by the patients themselves at the time they
experienced prodromal symptoms, by means of a modified version
of Algomed pump (Medtronic Inc., Minneapolis, Minnesota)
(Fig. 1).
A total of 27 patients with frequently recurrent VVS (median
number, 20), were studied (26 women; mean age, 49 years): 17
during the physician test and 10 during the patient test. All
patients had a reproducible positive response to at least two
baseline HUTTs performed according to the “Italian protocol”
(type of positive response: mixed in 11 patients, vasodepressor in
11 patients, and cardioinhibitory in 5 patients). All 27 patients had
a positive response during both tilt tests with phenylephrine and
placebo injection.
During the physician test (Table 1), the administration of
phenylephrine led to an immediate increase in blood pressure in 15
of 17 patients (88%). This increase reversed, a few seconds after
injection, prodromal symptoms and prevented syncope in nine
subjects (53%) and restored consciousness in six subjects (35%),
even though patients continued to be tilted upward at the same
angle. In only two patients (12%), both of whom had an asystolic
pause 3 s, was phenylephrine injection unsuccessful. Phenyleph-
rine was always well tolerated. The administration of placebo did
not prevent or abort syncope in any patient (p  0.001 compared
with phenylephrine).
During the patient test, all 10 patients studied were able to
activate the DDS appropriately. The delivery of phenylephrine was
successful in every subject (efficacy 100%) without the occurrence
of side effects. The administration of placebo was not effective in
any patient (p 0.001 compared with phenylephrine).
In the physician test, the mean time between onset of symptoms
and injection of phenylephrine or placebo did not differ signifi-
cantly (69 s vs. 58 s). After the injection of phenylephrine, the drug
took effect very soon (within 13  7 s), and all patients who
recovered consciousness did so within a mean of 32  17 s. The
maximum effect of phenylephrine was observed after 90  35 s.
Baseline values were restored in approximately 5 min. After the
injection of placebo, the mean time of syncope development was
32  23 s; tilting was stopped and patients were returned to the
supine position within 50  22 s. In the patient test, a similar
timing of the effects of phenylephrine and placebo injection was
observed.
All patients experienced premonitory symptoms at the time of
VVS. In the physician test, the mean duration of prodromal
symptoms was 101  40 s during the test with phenylephrine
injection and 90  35 s during the test with placebo injection. In
the patient test, the corresponding values were 123  39 s and
96  31 s, respectively.
In our study, phenylephrine proved to be significantly more
efficacious than placebo in preventing tilt-induced syncope. The
efficacy of phenylephrine, an alpha-agonist agent, was clearly due
to its potent vasoconstrictor effect. Indeed, the drug determined an
immediate marked increase in blood pressure, which interrupted
the VVS, even though the pre-existing reflex bradycardia increased
further as a result of baroreceptor activation. Phenylephrine was
not able to prevent syncope in only two patients, both of whom
had a severe cardioinhibitory response. Phenylephrine was safe and
well tolerated in all cases. Moreover, phenylephrine acted very
rapidly and had a short action of duration. Thus, phenylephrine
seems to be an ideal agent for a DDS for the treatment of VVS.
Other drugs have been evaluated for potential use in a DDS.
Ammirati et al. (1) assessed the efficacy of etilefrine, another
alpha-agonist agent, and found that it was successful in 87% of
cases as opposed to 20% when placebo was injected. In a previous
study, Santini et al. (2) observed a 70% efficacy using atropine, a
pure anticholinergic agent, versus a 22% success rate using placebo.
However, in these two studies, drugs and placebo were adminis-
tered randomly to different patients and not compared in the same
subjects. Moreover, in the Santini et al. (2) study, atropine and
placebo were injected during the very initial stage of the neuro-
mediated reflex.
In the present study, we found that, at the time of VVS, all
subjects experienced warning symptoms for a reasonably long
period of time. This period allowed the subjects to self-activate the
DDS appropriately and effectively. These results suggest that
prodromal symptoms may constitute quite a valuable marker of
incipient VVS and may serve as a “sensor” in a patient-activated
DDS.
Figure 1. Modified Algomed pump.
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Finally, in our study, all patients were able to activate easily the
Algomed system at the time of prodromal symptoms, and injection
of phenylephrine was effective in every patient. These results
indicate that the modified Algomed pump is an efficient prototype
of a patient-activated DDS for the treatment of VVS during
HUTT. Obviously, our data are experimental, and further studies
are needed to confirm these laboratory results in clinical practice.
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Association of Smoking With Improved Myocardial Perfusion and the Angiographic
Characterization of Myocardial Tissue Perfusion After Fibrinolytic Therapy for
ST-Segment Elevation Myocardial Infarction
To the Editor: ST-segment elevation myocardial infarction
(STEMI) may arise from different pathophysiologic processes
ranging from plaque rupture to endothelial surface erosion. In the
latter case, exposure of a denuded endothelium to a “high-risk
blood phenotype” of elevated procoagulant factors and activated
inflammatory cells may be the major trigger for thrombus forma-
tion. In particular, cigarette smoking is associated with increases in
circulating fibrinogen and tissue factor (1), suggesting that throm-
bus in smokers with STEMI may be more fibrin-rich and,
therefore, more amenable to fibrinolytic therapy.
Despite an increased risk of developing myocardial infarction,
smokers with STEMI have a lower mortality compared with
nonsmokers. This was first noted in the Thrombolysis In Myo-
cardial Infarction (TIMI)-2 trial and has been largely attributed to
fewer comorbidities and younger age among smokers. However,
smoking has also been independently associated with lower mor-
tality (2) and with better epicardial flow after fibrinolytic therapy
(3). Although we were unable to detect differences in myocardial
perfusion among a limited number of patients from older fibrino-
lytic trials (4), we hypothesized that in a larger population treated
with current fibrinolytic therapy, smoking might be associated
with improved myocardial perfusion as a potential unidentified
explanation of the “smokers’ paradox.”
Data were drawn from patients in the Integrilin and Tenecteplase
in Acute Myocardial Infarction (INTEGRITI), Enoxaparin and
Thrombolysis Reperfusion for Acute Myocardial Infarction
Table 1. Blood Pressure and Heart Rate During HUTT With Placebo and Phenyilephrine
Injection
Physician Test (n  15) Patient Test (n  10)
Phenylephrine Placebo Phenylephrine Placebo
Systolic blood pressure (mm Hg)
Supine 141 20 129  23 140 16 142  16
Tilting start 144 23 128  24 149 18 144  10
Symptoms onset 105 19 96  21 122 23 106  20
Injection 62  13 61  14 76 16 74  10
End point 121 19* 50  13 116 32* 59  9
Maximum effect 175 35 177  19
Diastolic blood pressure (mm Hg)
Supine 73  12 68  14 74 14 73  11
Tilting start 82  14 76  16 87 3 85  6
Symptoms onset 65  12 62  19 78 15 72  11
Injection 44  11 45  14 55 13 51  10
End point 73  10* 37  12 79 20* 39  8
Maximum effect 100 16 102  10
Heart rate (beats/min)
Supine 77  16 75  12 72 10 74  13
Tilting start 85  19 93  15 87 11 88  12
Symptoms onset 97  26 97  24 99 21 105  15
Injection 81  30 88  27 96 26 98  22
End point 68  25 75  21 70 21 75  26
Maximum effect 59 21 55  13
*Phenylephrine vs. placebo: p  0.01 (two-tailed paired Student t test).
End point  syncope or normal state of consciousness; HUTT  head-up tilt test.
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